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Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and
neck squamous cell carcinoma
Abstract
Background: Despite the high prevalence of epidermal growth factor receptor (EGFR) overexpression in
head and neck squamous cell carcinomas (HNSCCs), incorporation of the EGFR inhibitor cetuximab into
the clinical management of HNSCC has not led to significant changes in long-term survival outcomes.
Therefore, the identification of novel therapeutic approaches to enhance the clinical efficacy of cetuximab
could lead to improved long-term survival for HNSCC patients. Our previous work suggests that EGFR
inhibition activates the interleukin-1 (IL-1) pathway via tumor release of IL-1 alpha (IL-1α), although the
clinical implications of activating this pathway are unclear in the context of cetuximab therapy. Given the role
of IL-1 signaling in anti-tumor immune response, we hypothesized that increases in IL-1α levels would
enhance tumor response to cetuximab.
Methods: Parental and stable myeloid differentiation primary response gene 88 (MyD88) and IL-1 receptor
1 (IL-1R1) knockdown HNSCC cell lines, an IL-1R antagonist (IL-1RA), neutralizing antibodies to IL-1α
and IL-1β, and recombinant IL-1α and IL-1β were used to determine cytokine production (using ELISA) in
response to cetuximab in vitro. IL-1 pathway modulation in mouse models was accomplished by
administration of IL-1RA, stable overexpression of IL-1α in SQ20B cells, administration of rIL-1α, and
administration of a polyanhydride nanoparticle formulation of IL-1α. CD4+ and CD8+ T cell-depleting
antibodies were used to understand the contribution of T cell-dependent anti-tumor immune responses.
Baseline serum levels of IL-1α were measured using ELISA from HNSCC patients treated with cetuximab-
based therapy and analyzed for association with progression free survival (PFS).
Results: Cetuximab induced pro-inflammatory cytokine secretion from HNSCC cells in vitro which was
mediated by an IL-1α/IL-1R1/MyD88-dependent signaling pathway. IL-1 signaling blockade did not affect
the anti-tumor efficacy of cetuximab, while increased IL-1α expression using polyanhydride nanoparticles in
combination with cetuximab safely and effectively induced a T cell-dependent anti-tumor immune response.
Detectable baseline serum levels of IL-1α were associated with a favorable PFS in cetuximab-based therapy-
treated HNSCC patients compared to HNSCC patients with undetectable levels.
Conclusions: Altogether, these results suggest that IL-1α in combination with cetuximab can induce a T cell-
dependent anti-tumor immune response and may represent a novel immunotherapeutic strategy for EGFR-
positive HNSCCs.
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Abstract
Background: Despite the high prevalence of epidermal growth factor receptor (EGFR) overexpression in head and
neck squamous cell carcinomas (HNSCCs), incorporation of the EGFR inhibitor cetuximab into the clinical
management of HNSCC has not led to significant changes in long-term survival outcomes. Therefore, the
identification of novel therapeutic approaches to enhance the clinical efficacy of cetuximab could lead to improved
long-term survival for HNSCC patients. Our previous work suggests that EGFR inhibition activates the interleukin-1
(IL-1) pathway via tumor release of IL-1 alpha (IL-1α), although the clinical implications of activating this pathway
are unclear in the context of cetuximab therapy. Given the role of IL-1 signaling in anti-tumor immune response,
we hypothesized that increases in IL-1α levels would enhance tumor response to cetuximab.
Methods: Parental and stable myeloid differentiation primary response gene 88 (MyD88) and IL-1 receptor 1 (IL-1R1)
knockdown HNSCC cell lines, an IL-1R antagonist (IL-1RA), neutralizing antibodies to IL-1α and IL-1β, and recombinant
IL-1α and IL-1β were used to determine cytokine production (using ELISA) in response to cetuximab in vitro. IL-1
pathway modulation in mouse models was accomplished by administration of IL-1RA, stable overexpression of IL-1α in
SQ20B cells, administration of rIL-1α, and administration of a polyanhydride nanoparticle formulation of IL-1α. CD4+
and CD8+ T cell-depleting antibodies were used to understand the contribution of T cell-dependent anti-tumor
immune responses. Baseline serum levels of IL-1α were measured using ELISA from HNSCC patients treated with
cetuximab-based therapy and analyzed for association with progression free survival (PFS).
Results: Cetuximab induced pro-inflammatory cytokine secretion from HNSCC cells in vitro which was mediated by an
IL-1α/IL-1R1/MyD88-dependent signaling pathway. IL-1 signaling blockade did not affect the anti-tumor efficacy of
cetuximab, while increased IL-1α expression using polyanhydride nanoparticles in combination with cetuximab safely
and effectively induced a T cell-dependent anti-tumor immune response. Detectable baseline serum levels of IL-1α
were associated with a favorable PFS in cetuximab-based therapy-treated HNSCC patients compared to HNSCC
patients with undetectable levels.
Conclusions: Altogether, these results suggest that IL-1α in combination with cetuximab can induce a T cell-dependent
anti-tumor immune response and may represent a novel immunotherapeutic strategy for EGFR-positive HNSCCs.
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Background
Although EGFR is highly expressed in HNSCC tumors,
EGFR-targeted therapy using tyrosine kinase inhibitors
(TKIs) has failed in clinical trials for HNSCC [1–4]. The
EGFR monoclonal IgG1 antibody cetuximab is the only
FDA approved EGFR inhibitor for first-line treatment of
R/M HNSCC. Cetuximab-based therapy has relatively
high response (36%) and disease control rates (81%) but
is generally not curative and most patients will experi-
ence disease progression [5, 6]. Immunotherapy with
antibodies targeting programmed cell death protein-1
(PD-1) have shown great promise and are now FDA ap-
proved for R/M HNSCC as second-line therapy. Single
agent immunotherapy has only modest response rates
(13–16%) yet these responses, in contrast to
cetuximab-based therapy, are remarkably durable [7, 8].
However only a minority of patients derive benefit from
single-agent immunotherapies and improvements are
needed before routine use of anti-PD-1 agents as
first-line treatment for R/M disease. Nevertheless, the
relatively high response rates of cetuximab-based ther-
apy and the durable responses of immunotherapy pro-
vide a strong rationale for the development of novel
EGFR-targeted/immunotherapy combination regimens.
Previous work in our laboratory has shown that EGFR
inhibitors induce an upregulation of a variety of inflam-
matory and immune response pathways via IL-1 alpha
(IL-1α) release [9, 10]. The IL-1 pathway plays a critical
role in the regulation of immune and inflammatory re-
sponses to infections and sterile insults [11, 12]; and dys-
regulation of this pathway is involved in a number of
autoinflammatory disorders (e.g. fever, rashes, arthritis,
and organ-specific inflammation) [11]. The IL-1 pathway
is triggered when the ligands IL-1α and IL-1 beta (IL-1β)
bind to IL-1 receptor type I (IL-1R1) that forms a com-
plex with the IL-1 receptor accessory protein (IL-1RAcP)
and then recruits myeloid differentiation primary re-
sponse gene 88 (MyD88), IL-1 receptor-associated ki-
nases (IRAKs), and TRAF6 [11]. This pathway results in
NFκB and MAPK signaling leading to the expression of
IL-1 target genes that are involved in inflammation and
immune responses including additional IL-1 ligands that
promote a positive feed forward loop [11].
The clinical relevance of IL-1 pathway activation in
the context of tumor response to cetuximab is unclear.
IL-1 ligand gene expression has been associated with
poor prognosis and can induce the expression of a var-
iety of pro-tumor survival factors involved in immune
cell recruitment and angiogenesis [13, 14]. In fact, our
previous work has shown that IL-1 signaling plays an
important role in resistance to the EGFR TKI erlotinib
in HNSCC cells [15]. Conversely, IL-1 signaling has been
shown to play a role in tumor suppression via natural
killer (NK) and T cell-mediated cytotoxicity [16–22]
which are also major anti-tumor mechanisms of cetuxi-
mab [23–26]. Based on the overlapping roles of both
cetuximab and IL-1 signaling in anti-tumor immune re-
sponses, we investigated if increasing IL-1 signaling may
represent an effective immunotherapeutic strategy to
combine with cetuximab. We additionally explore the
potential of circulating IL-1α levels as a predictive bio-
marker of response to cetuximab-based chemotherapy in
a limited cohort of R/M HNSCC patients.
Materials and methods
Cell lines
Cal-27 HNSCC cells were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA).
SQ20B cells were gifted to our lab from Dr. Anjali Gupta
(Department of Radiation Oncology, University of Iowa,
IA, USA). MyD88 and IL-1R1 knockdown SQ20B cells
were generated as previously described here [9]. IL-1α
overexpressing SQ20B cells were generated using
Myc-DDK-tagged-human IL-1α cDNA (Origene).
TUBO-EGFR [27, 28] cells were gifted to our lab from
Dr. Yang-Xin Fu (Department of Pathology, University
of Chicago, Chicago, IL, USA). All cell lines were pas-
saged no more than 15 times. All HNSCC cell lines are
EGFR positive and are sensitive to EGFR inhibitors.
Cal-27 and SQ20B cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 0.1% gentamycin.
TUBO-EGFR cells were cultured in DMEM supple-
mented with 10% FBS, 10 mM HEPES, 1% non-essential
amino acids, and 1% penicillin/streptomycin. All cells
are adherent and were cultured in vented flasks at 37 °C
and 5% CO2 in a humidified incubator.
In vitro drug treatment
Cetuximab and anakinra (ANA) were purchased from
the inpatient pharmacy at the University of Iowa Hospi-
tals and Clinics. Human IgG was purchased from
Sigma-Aldrich (St. Louis, MO). Recombinant human
IL-1α (rIL-1α) and IL-1β (rIL-1β) were purchased from
R & D Systems (Minneapolis, MN). Neutralizing human
and mouse IL-1α (nIL-1α) and IL-1β (nIL-1β) antibodies
were purchased from Invivogen (San Diego, CA). Drugs
were added to cells at final concentrations of 1–100 μg/
mL cetuximab, 10 μg/mL ANA, 100 μg/mL IgG1, 1 μg/
mL nIL-1α/nIL-1β and 0.5 ng/mL rIL-1α/rIL-1β. The re-
quired volume of each drug was added directly to
complete cell culture media on cells to achieve the indi-
cated final concentrations for up to 48 h.
IL-1α polyanhydride nanoparticle synthesis
IL-1α-loaded polyanhydride nanoparticles were synthesized
using the anhydride monomers 1,8-bis(p-carboxyphenox-
y)-3,6-dioxaoctane (CPTEG) and 1,6-bis(p-carboxyphenoxy)
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hexane (CPH). First, a 20:80 CPTEG:CPH copolymer was
synthesized via melt polycondensation as previously de-
scribed [29, 30]. Next, 20:80 CPTEG:CPH nanoparticles en-
capsulating murine rIL-1α (Biolegend, San Diego, CA) were
synthesized using a solid-oil-oil double emulsion process
[31]. Briefly, 20:80 CPTEG:CPH polymer containing 1.5 wt.%
rIL-1α was dissolved 20mg/mL in methylene chloride. The
solution was sonicated for 30 s to ensure the components
were fully dissolved and evenly distributed. Nanoparticles
were then precipitated into chilled pentane (1:250 methylene
chloride:pentane) and collected via vacuum filtration. Nano-
particle morphology was verified with scanning electron mi-
croscopy (FEI Quanta 250, FEI, Hillsboro, OR) and their size
analyzed with ImageJ (ImageJ 1.48v, NIH). To observe the
release kinetics of IL-1α, nanoparticle suspensions of 10mg/
mL in PBS were sonicated to disperse particle aggregates
and incubated at 37 °C for approximately one week. Periodic-
ally, the suspensions were centrifuged, the supernatant was
collected, and the particles resuspended in fresh PBS. The
amount of released IL-1α in the supernatant was measured
using a microBCA assay (Thermo Fisher Scientific, Wal-
tham, MA). At the end of the experiment, the remaining
nanoparticles were placed in 40mM sodium hydroxide to
extract any remaining protein. The encapsulation efficiency
was determined by comparing the total amount of protein
released and extracted from the nanoparticles to the amount
theoretically encapsulated.
Enzyme-linked immunosorbent assay
Levels of IL-6, IL-8, IL-1α and IL-1β in the cell culture
media of drug-treated cells and levels of IL-1α in human
serum were determined by ELISA. Each cytokine was
detected according to the manufacturer’s protocol using
Human Quantikine ELISA Kits (R&D Systems, Minne-
apolis, MN). Colorimetric analysis was performed using
a Synergy H1 Hybrid Multi-Mode Reader (BioTek, Wi-
nooski, VT).
Western blot analysis
Cell lysates were standardized for protein content, resolved
on 4–12% SDS polyacrylamide gels, and blotted onto nitro-
cellulose membranes. Membranes were probed with rabbit
anti-MyD88 (1:500, Cell Signaling), anti-IL-1R1 (1:500,
Santa Cruz), and anti-beta-actin (1:5000, Thermo Scien-
tific). Antibody binding was detected by using an ECL
Chemiluminescence Kit (Amersham).
Tumor cell implantation
Male and female athymic nu/nu or BALB/c mice (4–6
weeks old) were purchased from Envigo Laboratories
(Huntingdon, Cambridgeshire, United Kingdom). Mice
were housed in a pathogen-free barrier room in the Ani-
mal Care Facility at the University of Iowa and handled
using aseptic procedures. All procedures were approved
by the IACUC committee of the University of Iowa and
conformed to the guidelines established by the NIH. Mice
were allowed at least 3 days to acclimate prior to begin-
ning experimentation, and food and water were made
freely available. SQ20B or Cal-27 cells (1 × 106 cells/
mouse) were inoculated into athymic nude mice and
TUBO-EGFR cells (5 × 105 cells/mouse) were inoculated
into BALB/c mice by subcutaneous injection of 0.1 mL ali-
quots of saline containing cancer cells into the right flank
using 26 gauge needles.
In vivo drug administration
Drug treatment commenced 3 days after tumor inocula-
tion. For the IL-1 blockade experiments, male and female
Cal-27 and SQ20B tumor-bearing athymic nu/nu mice
(n = 12 mice/group, 6 male/6 female) and male and female
TUBO-EGFR-bearing BALB/c mice (n = 10 mice/group, 5
male/5 female) were randomized into the following treat-
ment groups: Control group - Mice were administered sa-
line daily and 2mg/kg IgG i.p twice per week. IL-1R
antagonist (anakinra [ANA]) group - ANA was adminis-
tered at 10mg/kg i.p. daily. Cetuximab (CTX) group -
CTX was administered at 2mg/kg (or 8mg/kg for
TUBO-EGFR tumors [32]) i.p. twice per week. CTX+
ANA group - mice were administered both CTX and ANA
i.p. at the doses/schedules indicated above. For the IL-1α
overexpressing experiment, female athymic nu/nu mice
(n = 4–5 mice/group) bearing IL-1α overexpressing xeno-
grafts (#20) or control transfected xenografts (#16) were
treated with either CTX (2mg/mouse twice/week i.p.) or
IgG as a control. For the IL-1 pathway activation experi-
ments, male and female athymic nu/nu mice (n = 10 mice/
group, 5 male/5 female) bearing SQ20B xenograft tumors
or BALB/c mice (n = 10 mice/group, 5 male/5 female)
bearing TUBO-EGFR tumors were treated with 2mg/kg
(or 8mg/kg for TUBO-EGFR tumors) CTX i.p. twice/week
with or without 0.6 μg human rIL-1α (for SQ20B tumors)
or murine rIL-1α (for TUBO-EGFR tumors). IgG and H2O
were used as controls. IL-1α was given at least half an hour
prior to CTX or IgG administration, and again 24 h later
totaling 4 doses of CTX and IgG and 8 doses of IL-1α and
H2O. For the IL-1α nanoparticle experiment, female
BALB/c mice (n = 9–10 mice/group) bearing TUBO-EGFR
tumors were treated with 8mg/kg CTX i.p. twice/week
with or without IL-1α-NPs (0.5mg NPs containing 7.5 μg
IL-1α, on the first day of treatment). IgG and empty nano-
particles (EMP-NP) were used as controls. For the T cell
depletion experiments, female BALB/c mice (n = 9–10
mice/group) bearing TUBO-EGFR tumors were treated
with cetuximab (CTX, 8mg/kg twice/week) in combin-
ation with a single i.p. dose on treatment day 1 of
IL-1α-NPs with or without anti-CD4 (100 μg (clone
GK1.5)) or anti-CD8 (300 μg (clone 53–6.7)) 1 and 3 days
prior to tumor inoculation, and every 3–4 days after tumor
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inoculation. All treatments were given for the duration of
2 weeks with exception of the IL-1α overexpressing SQ20B
experiment where treatment ended after 3 weeks. Mice
were evaluated daily and tumor measurements and weights
were taken three times per week using Vernier calipers.
Tumor volumes were calculated using the formula: tumor
volume = (length × width2)/2 where the length was the lon-
gest dimension, and width was the dimension perpendicu-
lar to length. Mice were euthanized via CO2 gas
asphyxiation when tumor diameter exceeded 1.5 cm in any
dimension. Tumor growth curves were plotted over time
and stopped after a mouse in any treatment group reached
euthanasia criteria.
Flow cytometry
For the assessment of splenocytes and tumor-infiltrating
immune cells, spleens and tumors were harvested imme-
diately after sacrificing mice via CO2 asphyxiation. Tu-
mors were digested with 100 U/mL collagenase type I
and 100 μg/mL DNAse in RPMI + 10% FBS at 37 °C for
30 min. Digested tumors and spleens were forced
through 70 μm filters and washed 3 times with FACS
separation buffer supplemented with 10% FBS. Cells
were washed with FACS buffer without FBS, counted,
pelleted, and resuspended at 1 × 106 cells / 100 μL. Cells
were stained with various murine antibodies including
CD3 (GK1.5 and 17A2), CD4 (GK1.5), CD8 (53–6.7),
CD19 (6D5), CD25 (PC61), CD49b (DX5), CD69
(H1.2F3), CD122 (TM-β1), KLRG1 (2F1/KLRG1) and
PD-1 (29F.1A12) (BioLegend) for 30 min at 4 °C pro-
tected from light. After staining, cells were washed with
FACS buffer, and resuspended in 2% paraformaldehyde
in FACS buffer (50 μL/well). Flow cytometry was per-
formed using a BD FACSCANTO II cytometer.
HNSCC patient study
Baseline serum samples from 11 recurrent and/or metastatic
(R/M) HNSCC patients (Additional file 1: Table S1) sched-
uled for cetuximab-based chemotherapy (i.e. carboplatin,
cisplatin, 5-fluorouricil [5-FU], paclitaxel) at the University
of Iowa Hospitals and Clinics (UIHC) Holden Comprehen-
sive Cancer Center (HCCC) were collected. Serum IL-1α
levels were measured by ELISA and interrogated for associa-
tions with clinical outcomes. This study was approved by
the University of Iowa Institutional Review Board (IRB ap-
proval #201302782). This study was conducted in accord-
ance with ethical standards presented in the 2013
Declaration of Helsinki. All subjects provided their informed
consent in written form for participation in the study.
Statistical analysis
Statistical analysis was done using GraphPad Prism ver-
sion 5 for Windows (GraphPad Software, San Diego, CA).
Differences between 3 or more means were determined by
one-way ANOVA with Tukey post-tests. Two-way
ANOVA will be used to determine differences among cell
lines and drug treatment groups. Linear mixed effects
regression models were used to estimate and compare the
group-specific change in tumor growth curves.
Kaplan-Meier survival curves were generated to illustrate
the different survival rates over time. Differences in me-
dian survival were determined by Log-rank (Mantel-Cox)
test. All statistical analysis was performed at the p < 0.05
level of significance.
Results
Cetuximab induces secretion of pro-inflammatory
cytokines
To determine if cetuximab triggers proinflammatory cyto-
kine release from HNSCC cells, Cal-27 and SQ20B cells
were treated with 1, 10 and 100 μg/mL cetuximab for 48 h
and cell culture media was analyzed for IL-1α, IL-6 and
IL-8 by ELISA. In Cal-27 cells cetuximab at a dose of
100 μg/mL significantly increased IL-1α (Fig. 1A), IL-6
(Fig. 1B) and IL-8 (Fig. 1C), while in SQ20B cells cetuxi-
mab increased IL-1α (Fig. 1A) and IL-8 (Fig. 1C) at
100 μg/mL and IL-6 at all cetuximab doses tested (Fig. 1B).
The observed effects did not appear to be dose-dependent
in general. IL-1β was not detectable in any of the treated
samples (data not shown). These data show that cetuximab
has the ability to trigger the release of pro-inflammatory cy-
tokines directly from HNSCC cells.
MyD88 knockdown suppresses cetuximab-induced
cytokine secretion
A well-established mechanism of pro-inflammatory cyto-
kine production involves the cytosolic adaptor protein
MyD88, which acts through intermediaries to induce NFκB
activation and cytokine expression [33]. Cell lines derived
from MyD88 stable knockout clones (shMyD88#2,
shMyD88#9, Fig. 1D inset) demonstrated significantly re-
duced IL-1α (Fig. 1D), IL-6 (Fig. 1E) and IL-8 (Fig. 1F) in
the presence of cetuximab compared to control cells
(shControl) with the exception of IL-8 secretion from the
shMyD88#2 clone at 10 and 100 μg/mL (Fig. 1F). MyD88
knockdown also significantly reduced IL-1α baseline levels
(Fig. 1D). These data support the role of MyD88-dependent
signaling in cetuximab-induced cytokine production.
IL-1R1 knockdown suppresses cetuximab-induced
cytokine secretion
MyD88 is required for the activity of members of the Toll/
Interleukin-1 receptor (TIR) superfamily which include
Toll-like Receptors (TLRs), the IL-1R, and the IL-18 Recep-
tor (IL-18R) [33]. Activation of these receptors lead to the
recruitment of MyD88 via its TIR domain, resulting in
NFκB activation and expression of pro-inflammatory cyto-
kines including IL-1α, IL-6 and IL-8 [33]. We previously
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found that erlotinib-induced secretion of pro-inflammatory
cytokines was mediated by IL-1R/MyD88-dependent sig-
naling (and not TLR or IL-18R signaling [9]), therefore we
determined if these results could be duplicated with cetuxi-
mab. Cell lines derived from IL-1R1 stable knockout clones
(shIL-1R1#1, shIL-1R1#2, Fig. 1G inset) were assessed and
demonstrated significantly reduced IL-1α at baseline and in
the presence of cetuximab (with exception of the
shIL-1R1#1 clone at 1 and 100 μg/mL (Fig. 1G)) supporting
previous reports of IL-1α as a gene target of IL-1 signaling
and the feed-forward nature of IL-1 signaling. The IL-1R1
knockout clones also demonstrated significantly reduced
IL-6 at baseline and in the presence of cetuximab with ex-
ception of the shIL-1R1#1 clone at 10 μg/mL (Fig. 1H); and
significantly reduced IL-8 in the presence of cetuximab in
the shIL-1R1#1 clone at all doses tested (Fig. 1I). In the
shIL-1R#2 clone, IL-8 was significantly suppressed at base-
line and not detected in response to cetuximab at all doses
tested (Fig. 1I). Furthermore, using IL-6 as an endpoint of
IL-1 signaling, we showed that pretreatment with the IL-1
receptor antagonist (IL-RA/anakinra [ANA]) significantly
reduced baseline and cetuximab-induced secretion of IL-6
from both cell lines (Fig. 2A). Together these results point
to the induction of cytokine secretion via an IL-1R/
MyD88-dependent pathway in response to cetuximab.
Cetuximab-induced IL-1 signaling is triggered by IL-1α
release
To confirm which ligand(s) (IL-1α or IL-1β) may be respon-
sible for activating the IL-1 pathway, we again used IL-6 as
Fig. 1 Cetuximab induces secretion of pro-inflammatory cytokines via IL-1R/MyD88 signaling. Cal 27 and SQ20B HNSCC cells (a-c), SQ20B cells
derived from MyD88 stable knockout clones (shMyD88 #2, shMyD88 #9) and control cells (shControl) (d-f), and SQ20B cells derived from IL-1R1
stable knockout clones (shIL-1R #1, shIL-1R #2) and control cells (shControl) (g-i) were treated with 1–100 μg/mL cetuximab (CTX) or 100 μg/mL
IgG for 48 H. media was collected and ELISAs were performed to measure IL-1α (a, d, g), IL-6 (b,e,h), and IL-8 (c,f,i). Cells were analyzed for
expression of MyD88 (D inset) and IL-1R1 (G inset) by Western blot and β-actin was used as a control. Error bars = SEM. N = 3. ¥:p < 0.05 vs.
respective IgG treatment; *p < 0.05 vs. respective shControl cell line. ND = not detected
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an endpoint since IL-1 signaling is well known to trigger the
release of IL-6 via IL-1R1 binding [34]. We found that
neutralization of IL-1α (but not IL-1β) significantly sup-
pressed cetuximab-induced IL-6 secretion (Fig. 2B) suggest-
ing that IL-1α in particular may be responsible for
cetuximab-induced IL-1R1/MyD88 signaling and cytokine
(including IL-6) release. Exogenous human rIL-1α dramatic-
ally and significantly increased IL-6 secretion in the absence
and presence of cetuximab (Fig. 2C) supporting IL-6 expres-
sion/secretion as an endpoint of IL-1 signaling. Surprisingly,
this effect was not observed with rIL-1β even though both
ligands bind the same receptor (Fig. 2C). Together these
results suggest that IL-1α, but not IL-1β, is responsible for
activation of IL-1R1/MyD88 signaling and cytokine secre-
tion triggered by cetuximab in HNSCC cells.
IL-1 blockade does not affect the anti-tumor activity of
cetuximab
Given that IL-1 signaling may play both pro-survival and
anti-tumor roles in cancer biology, we wanted to deter-
mine the clinical relevance (if any) of cetuximab-induced
IL-1 signaling. We showed that IL-1 blockade using
anakinra (which binds both human and mouse IL-1R1)
did not significantly affect tumor response to cetuximab
in Cal-27 (Fig. 2D) and SQ20B xenograft tumors (Fig. 2E).
Similar results were observed in an immunocompetent
TUBO-EGFR/BALB/c syngeneic mouse model (Fig. 2F)
which utilizes the murine TUBO cell line [28] that was
transfected with human EGFR [26, 32] - since cetuximab
binds to human and not murine EGFR. Interestingly, we
found that in the Cal-27 xenograft model, tumor-bearing
female mice demonstrated significantly increased tumor
growth in response to anakinra as a single agent
(Additional file 2: Figure S1A), whereas male mice did not
demonstrate this phenomenon (Additional file 2: Fig.
S1B). These sex differences were not observed in the
SQ2OB (Fig. 2E) or TUBO-EGFR (Fig. 2F) mouse models.
Altogether the data suggests that IL-1 blockade did not
significantly affect the anti-tumor efficacy of cetuximab.
Increased IL-1α may enhance the anti-tumor efficacy of
cetuximab in vivo
Since IL-1 signaling may be involved in anti-tumor re-
sponse, we next sought to address if increasing IL-1α
Fig. 2 IL-1 blockade does not improve the anti-tumor efficacy of cetuximab. a Cal 27 and SQ20B HNSCC cells were pretreated with 10 μg/mL
anakinra (ANA) for 4 h with or without 100 μg/mL cetuximab (CTX) for 48 h. IgG and PBS were used as controls. b Cal 27 and SQ20B HNSCC cells
were pretreated with 1 μg/mL nIL-1αab or 1 μg/mL nIL-1βab for 4 h with or without 100 μg/mL CTX for 48 h. IgG was used as a control. c Cal 27
and SQ20B HNSCC cells were pretreated with 0.5 ng/mL human rIL-1α or 0.5 ng/mL human rIL-1β for 4 h with or without 100 μg/mL CTX for 48
h. IgG was used as a control. Media was collected and ELISAs were performed to measure IL-6 secretion. N = 3–4. *: p < 0.05 vs. IgG; **: p < 0.05
vs CTX and IgG. d-f: Athymic nu/nu mice (n = 12 [n = 6 male/n = 6 female]) bearing Cal 27 (d) and SQ20B (e) tumors and BALB/c mice (n = 10
[n = 5 male/n = 5 female]) bearing TUBO-EGFR tumors (f) were treated with CTX (2 mg/kg [8 mg/kg for TUBO-EGFR tumors]) twice weekly and
anakinra (10 mg/kg daily) i.p. for two weeks. Tumors were measured three times/week. Tumor growth curves shown were stopped after a mouse
in any treatment group reached euthanasia criteria. Error bars = SEM. *:p < 0.05
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expression could enhance the efficacy of cetuximab. To
accomplish this we overexpressed IL-1α in the SQ20B cell
line using Myc-DDK-tagged-human IL-1α cDNA
(Origene). An overexpressing IL-1α clone (#20, Fig. 3
inset) and 1 control clone (#16, Fig. 3 inset) were grown in
a SQ20B xenograft model in female athymic nude mice in
the presence of IgG or cetuximab. We found that the
IL-1α-overexpressing tumors treated with cetuximab (#20
CTX) grew significantly slower compared to the IgG (#16
IgG) and cetuximab-treated (#16 CTX) control clones,
and the IgG-treated IL-1α-overexpressing clones (#20
IgG) (Fig. 3) suggesting that increased tumor-derived
IL-1α may enhance tumor response to cetuximab.
Systemic delivery of recombinant IL-1α demonstrates
anti-tumor activity in immunocompetent mice
We next investigated if systemic i.p. delivery of recombin-
ant IL-1α (rIL-1α) would enhance tumor response to
cetuximab. In SQ20B tumor-bearing athymic nude mice
we observed that cetuximab nor human rIL-1α showed sig-
nificant anti-tumor activity during the 2 week treatment
period (Fig. 4A) however, tumor growth in the human
rIL-1α in combination with cetuximab-treatment group
was significantly slower compared to the other treatment
groups (Fig. 4A). Note that human rIL-1α can bind to mur-
ine IL-1R1 [35]. When this experiment was attempted in
the immunocompetent TUBO-EGFR/BALB/c syngeneic
mouse model [26, 28, 32] using murine rIL-1α, we again
observed no significant difference with cetuximab as a
single agent compared to control-treated tumors (Fig. 4B)
over the 2 week treatment period. The non-significance of
cetuximab in this tumor model was driven by the female
mice (Additional file 3: Figure S2B) which did not respond
to cetuximab in contrast to the male mice which did
respond (Additional file 3: Figure S2A). Murine rIL-1α as a
single agent was equally as effective as rIL-1α + cetuximab
at significantly suppressing tumor growth (Fig. 4B), al-
though this observation may again be influenced by gender
differences since murine rIL-1α as a single agent demon-
strated superior anti-tumor activity compared to all other
treatment groups in female mice (Additional file 3: Figure
S2B) and not male mice (Additional file 3: Figure S2A). We
summarize here that in immunocompetent mice, IL-1α as
a single agent and in combination with cetuximab demon-
strates anti-tumor activity and that gender differences influ-
ence drug response in this mouse model.
Treatment with recombinant IL-1α triggers weight loss
Although these data demonstrate the anti-tumor proper-
ties of rIL-1α in immunodeficient mice in combination
with cetuximab (Fig. 4A) and as a single agent in im-
munocompetent mice (Fig. 4B), unfortunately (but not
unexpectedly) all mice that were treated with human or
mouse rIL-1α in these experiments exhibited significant
side effects including weight loss (Fig. 4C, D), diarrhea
and lethargy. These side effects resulted in shortening
the drug treatment time from 3 weeks to 2 weeks as ori-
ginally planned. In the immunodeficient mice, there was
an initial decrease in body weight in all mice treated
with human rIL-1α over the first week of treatment
which gradually recovered to that of non-rIL-1α-treated
mice (Fig. 4C) after the 2 week treatment period. In the
immunocompetent model, the body weights of murine
rIL-1α-treated BALB/c mice steadily declined over the 2
week treatment period (Fig. 4D) with no recovery as ob-
served in the immunodeficient mice (Fig. 4C) resulting
in the euthanization of these mice and early termination
of the experiment. Intestines (including small and large
intestine with attached mesenteric fat and sometimes
pancreas) were made into Swiss rolls and evaluated to
determine, if possible, the cause of diarrhea in these
mice. There was multifocal moderate and in some cases
Fig. 3 IL-1α overexpression enhances the anti-tumor efficacy of cetuximab. Female athymic nu/nu mice bearing IL-1α overexpressing (#20) or
control (#16) SQ20B tumors were treated with cetuximab (CTX, 2 mg/kg, twice/week) or IgG for 3 weeks. Overexpression was confirmed by ELISA
(inset). Tumors were measured three times weekly. Tumor growth curves shown were stopped after a mouse in any treatment group reached
euthanasia criteria. Error bars = SEM. N = 4–5 mice/treatment group. *: p < 0.05
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marked mesenteric inflammation, composed primarily of
neutrophils, macrophages, lymphocytes and plasma cells
in mice treated with rIL-1α (rIL-1α alone or CTX+
rIL-1α) while those in the non-rIL-1α-treatment groups
(CON or CTX) did not show the same infiltrates
(Additional file 4: Figure S3). These results suggest that
the repeated i.p. administration of rIL-1α may be trigger-
ing a dramatic pro-inflammatory response resulting in
peritonitis, diarrhea, and weight loss, and that alternate
delivery methods of rIL-1α may be a promising strategy
as a single agent and in combination with cetuximab.
Nanoparticle delivery of IL-1α enhances cetuximab
activity
In an attempt to circumvent the side effects observed with
repeated i.p. rIL-1α delivery, we synthesized a polyanhy-
dride nanoparticle formulation as a possible safer alterna-
tive method that would allow for prolonged IL-1α
exposure with only a single administration to mice. A
20:80 CPTEG:CPH copolymer was used to encapsulate
murine rIL-1α as a 1.5% IL-1α 20:80 CPTEG:CPH nano-
particle (IL-1α-NP) formulation. The IL-1α-NPs exhibited
similar morphology and size (192.7 ± 67.5 nm; Add-
itional file 5: Figure S4A) as seen in previous work [31].
The release kinetics of IL-1α demonstrated a burst release
with greater than 90% of the payload being released within
the first 24 h, and the remainder slowly released over the
next 5 days (Additional file 5: Figure S4B). The encapsula-
tion efficiency was found to be 61.6 ± 6.8%. Empty 20:80
CPTEG:CPH nanoparticles (EMP-NPs) were synthesized
for use as a control. We observed that a single dose of
IL-1α-NPs (0.5mg NPs containing 7.5 μg IL-1α) i.p. on
Day 1 of treatment in combination with cetuximab (8mg/
mouse, twice/week for 2 wks) (CTX + IL-1α-NP) to fe-
male TUBO-EGFR-bearing BALB/c mice demonstrated
significantly reduced tumor growth compared to IgG +
EMP-NP, CTX+ EMP-NP, and IgG + IL-1α-NP treatment
groups (Fig. 5A). However, when we plotted the tumor
Fig. 4 Tumor response to recombinant IL-1α differs between immunodeficient and immunocompetent mouse models. Athymic nu/nu mice (n =
10 [n = 5 male/n = 5 female]) bearing SQ20B tumors (a, c) or BALB/c mice (n = 10 [n = 5 male/n = 5 female]) bearing TUBO-EGFR tumors (b, d)
were treated with cetuximab (CTX, 2 mg/kg [8 mg/kg for TUBO-EGFR tumors], twice/week) with or without 0.6 μg human (a, c) or murine (b, d)
recombinant IL-1α (rIL-1α) for 2 weeks. IgG and H2O were used as controls. IL-α was given at least half an hour prior to CTX or IgG administration,
and again 24 h later totaling 4 doses of CTX and IgG, and 8 doses of IL-1α and H2O. Tumor growth (a, b) and mouse weights (C,D) were
measured 3–5 times per week. Tumor growth curves shown were stopped after a mouse in any treatment group reached euthanasia criteria.
Error bars = SEM. *: p < 0.05
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growth trajectory of individual mice from each treatment
group (Fig. 5B-E), we observed that CTX+ IL-1α-NP--
treated mice caused complete tumor regression in almost
all mice (8/9) in this treatment group (Fig. 5E) compared
to IgG + EMP-NP (2/10, Fig. 5B), CTX+ EMP-NP (3/10,
Fig. 5C), and IgG + IL-1α-NP (6/10) (Fig. 5D). Import-
antly, there was no notable weight loss (Fig. 5F), diarrhea
or other obvious side effects due to IL-1α-NP treatment
over the treatment period. These data suggest that a single
administration of a polyanhydride CPTEG:CPH nanopar-
ticle formulation of IL-1α may be a relatively safe and ef-
fective option for IL-1α delivery as a single agent and in
combination with cetuximab.
Anti-tumor response to CTX + IL-1α-NP is T-cell
dependent
Because cetuximab in combination with rIL-1α showed
some anti-tumor activity in athymic nude mice where NK
cells (and not T cells) are present (Fig. 4A), and cetuximab
along with IL-1 ligands have been previously reported to
activate NK cell activity, we initially proposed that NK cells
may be involved in the anti-tumor immune response to
CTX+ IL-1α-NP. However, immune cells isolated from
spleens of CTX+ IL-1α-NP-treated mice demonstrated no
differences in the frequency of NK cells or activated NK
cells in the spleen (Additional file 6: Figure S5) or tumors
(Additional file 7: Figure S6) compared to the other treat-
ment groups. However, spleens from mice administered
CTX+ IL-1α-NP showed significantly decreased percent-
ages of PD-1+ CD4+ T cells (Fig. 5G), significantly increased
percentages of CD8+ T cells (Fig. 5H), and significantly de-
creased CD25+ CD8+ T cells compared to IgG + EMP-NP
(Fig. 5I). Percentages of CD69+ CD4+ and IFNγ+ CD8+ T
cells were elevated in tumors from CTX+ IL-1α-NP--
treated mice but did not reach statistical significance com-
pared to the other treatment groups (Additional file 8:
Figure S7). To further interrogate the role of T
cell-dependent immune response, female BALB/c mice
bearing TUBO-EGFR tumors were treated with CTX+
IL-1α-NP (Fig. 6A,B) as already described in Fig. 5 with or
without anti-CD4 (100 μg (clone GK1.5)) (Fig. 6A,C) or
anti-CD8 (300 μg (clone 53–6.7)) (Fig. 6A,D) 1 and 3 days
prior to tumor inoculation, and every 3–4 days after tumor
inoculation. Specific depletion of CD4+ (Fig. 6E) and CD8+
T cells (Fig. 6F) from tumors was confirmed by flow cytom-
etry. Both CD4+ and CD8+ T cell depletion significantly re-
versed the anti-tumor effect of CTX+ IL-1α-NP, and CD8+
T cell depletion was significantly more effective than CD4+
T cell depletion at reversing the anti-tumor effect of CTX
+ IL-1α-NP (Fig. 6A). Additionally spaghetti plots of indi-
vidual mice in each of the treatment groups showed
complete regression in 9/10 mice in the CTX+ IL-1α-NP
treatment group (Fig. 6B) compared to no tumor regression
in the CTX+ IL-1α-NP + anti-CD4 (Fig. 6C) and CTX+
IL-1α-NP + anti-CD8 (Fig. 6D) treatment groups. These re-
sults suggest that the anti-tumor mechanism of CTX+
IL-1α-NP involves a T cell-dependent immune response.
Increased serum IL-1α levels may predict favorable
progression-free survival (PFS) in R/M HNSCC patients
treated with cetuximab-based therapy
If IL-1α has the potential to increase T cell anti-tumor re-
sponses, we proposed that increased circulating levels of
IL-1α may represent a favorable anti-tumor immune re-
sponse compared to lower IL-1α levels and would perhaps
predict a more favorable response to cetuximab-based ther-
apy - since T cell activity is an important mechanisms of ac-
tion for cetuximab efficacy. We obtained pre-treatment
serum samples from a cohort of 11 consented patients at
the UIHC who were treated with cetuximab monotherapy
or cetuximab-based chemotherapy (i.e. carboplatin, cis-
platin, 5-FU, paclitaxel) and had available clinical outcome
data. Analysis of IL-1α levels by ELISA revealed that IL-1α
levels varied widely among the patients and ranged from
undetectable (i.e. below limit of detection) to 418 pg/mL.
Differences between pre-treatment IL-1α levels in patients
with stable disease (SD, (n = 6)) compared to progressive
disease (PD, (n = 5)) according to RECIST criteria were not
significant (data not shown). There were also no differences
in demographic or clinicopathological parameters between
the 2 patient cohorts (Additional file 1: Table S1). None of
the patients achieved a response of partial response (PR) or
complete response (CR). Five of the patients had undetect-
able serum levels of IL-1α and 6 patients had detectable
levels. Patients with detectable (n = 5) vs undetectable (n =
6) IL-1α levels were compared with time to progression.
We found significantly longer PFS in patients with detect-
able IL-1α (median survival = 224 days) compared to un-
detectable (median survival = 132 days) IL-1α by ELISA
(Fig. 7). These data suggest that circulating IL-1α levels
may be promising as a predictive indicator of PFS in
cetuximab-treated HNSCC patients and warrants further
investigation in this area.
In summary our data indicate that cetuximab induces the
secretion of pro-inflammatory cytokines which is triggered
by the release of IL-1α and subsequent IL-1R1/MyD88-de-
pendent signaling (Figs. 1, and 2). The release of IL-1α ap-
pears to be associated with an anti-tumor response since
increased rIL-1α can induce tumor regression as a single
agent in immunocompetent mice (Figs. 4B, and 5D) and
enhance the anti-tumor activity of cetuximab (Fig. 5A).
IL-1α-NPs were observed to be a relatively safe and effect-
ive option for IL-1α delivery (Fig. 5F) and the anti-tumor
activity of the combination of cetuximab and IL-1α-NP was
T-cell dependent (Fig. 6). Finally, detectable baseline serum
levels of IL-1α were associated with significantly longer PFS
in a limited cohort of R/M HNSCC patients treated with
cetuximab-based chemotherapy compared to undetectable
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levels (Fig. 7). Altogether, the results presented here suggest
that IL-1α in combination with cetuximab can induce a T
cell-dependent anti-tumor immune response and may
represent a novel immunotherapeutic strategy for
EGFR-positive HNSCCs. This work also suggests that
circulating IL-1α as a predictive biomarker for clinical out-
comes to cetuximab-based therapy for HNSCC patients is
worthy of further investigation.
Discussion
The key findings of the data presented here center around
the induction of an IL-1α/IL-1R/MyD88-dependent signal-
ing pathway due to cetuximab treatment in HNSCC cells,
and that IL-1α may be a promising immunotherapeutic
strategy alone and in combination with cetuximab for the
treatment of HNSCC. The ability of cetuximab to induce
the secretion of pro-inflammatory cytokines such as IL-1α,
IL-6 and IL-8 directly from HNSCC cells (Fig. 1) is sup-
ported by our previous work showing that a panel of EGFR
inhibitors (i.e. cetuximab, panitumumab, erlotinib, lapati-
nib) increased the secretion of cytokines such as IL-4, IL-6,
IL-8, GM-CSF and IFNγ [10]. The ability of cetuximab to
induce the secretion of cytokines is consistent in both
SQ20B and Cal-27 cell lines although variability in the ex-
tent of cytokine secretion is observed between experimental
replicates (Fig. 1). This variability may be due to normal
slight differences in EGFR ligand (EGF, TGFα) levels in
serum-containing cell culture media [36] which can affect
Fig. 5 Nanoparticle delivery of IL-1α demonstrates anti-tumor efficacy. a Female BALB/c mice (n = 9–10 mice/treatment group) bearing TUBO-
EGFR tumors were treated with cetuximab (CTX, 8 mg/kg, twice/week) for 2 weeks with or without a single administration of IL-1α nanoparticles
(IL-1α-NPs (0.5 mg NPs containing 7.5 μg IL-1α)) on the first day of treatment. IgG and empty nanoparticles (EMP-NP) were used as controls.
Tumor volumes were measured three times per week. Tumor growth curves shown were stopped after a mouse in any treatment group reached
euthanasia criteria. *:p < 0.05. Error bars = SEM. b-e: Shown are spaghetti plots for each individual mouse in each treatment group shown in A. F:
Mouse weights were measured three times per week. g-i: Spleens were harvested after therapy and PD-1 + CD4+ T cells (g), CD8+ T cells (h) and
CD25 + CD8+ T cells (i) were analyzed using flow cytometry. Error bars = SDM. N = 4–9 per group. *: p < 0.05 vs IgG
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the efficacy of cetuximab binding to EGFR. Despite this
variability, MyD88 and IL-1R1 knockdown was able to sup-
press cetuximab-induced cytokine production (Fig. 1D-I),
and in some cases baseline cytokine levels confirming that
IL-1R1/MyD88-dependent signaling is involved in cytokine
production.
The results point to IL-1α as the ligand responsible for
activation of the IL-1R1 since IL-1α but not IL-1β was
detectable by ELISA after cetuximab treatment (Fig.
1A,D,G), and neutralization of IL-1α (but not IL-1β ac-
tivity) significantly suppressed cetuximab-induced IL-6
secretion (Fig. 2B). Interestingly, administration of
rIL-1α (but not rIL-1β) triggered the expression and se-
cretion of IL-6 despite both ligands being able to bind
and activate the IL-1R1 (Fig. 2C). The reason for this is
unclear although expression of the soluble IL-1R2
(sIL-1R2) may be involved. The IL-1R2 functions as an
IL-1 decoy receptor and is structurally similar to IL-1R1
except its cytoplasmic domain is truncated, and it lacks
a TIR region rendering this receptor incapable of trans-
membrane signaling [37]. Membrane and soluble forms
of the IL-1R2 exist and generation of sIL-1R2 can be
Fig. 6 The anti-tumor effects of cetuximab+IL-1α-NP are T cell dependent. Female BALB/c mice (n = 9–10 mice/treatment group) bearing TUBO-
EGFR tumors were treated with cetuximab (CTX, 8 mg/kg twice/week) in combination with a single i.p. dose on treatment day 1 of IL-1α-NPs (0.5
mg NPs containing 7.5 μg IL-1α) (CTX + IL-1α-NP (a,b) with or without anti-CD4 (100 μg (clone GK1.5)) (a,c) or anti-CD8 (300 μg (clone 53–6.7))
(a,d) 1 and 3 days prior to tumor inoculation, and every 3–4 days after tumor inoculation. Treatment duration was 3 weeks. Tumor volumes were
measured three times per week. Tumor growth curves shown were stopped after a mouse in any treatment group reached euthanasia criteria.
Error bars = SEM. *:p < 0.05. b-d: Shown are spaghetti plots for each individual mouse in each treatment group shown in a. Tumors from female
BALB/c mice bearing TUBO-EGFR tumors (n = 3–4) were treated as described in A and harvested after 2 weeks of therapy for validation of CD4+ T
cell (E) and CD8+ T cell (F) depletion by flow cytometry. *:p < 0.05 vs NT, **:p < 0.05 vs anti-CD4. Error bars = SDM
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due to matrix metalloproteinase cleavage of full-length
membrane bound IL-1R2 into 45–47 kDa sIL-1R2 or by
alternative splicing [37]. Prior studies have shown that
sIL-1R2 binds to IL-1β with a higher affinity (10− 10 M)
compared to IL-1α (10− 8 M) [38–40] and the IL-1β/
sIL-1R2 disassociation rate is quite low and considered
irreversible [41]. The preferential binding of sIL-1R2 to
IL-1β prevents IL-1β from activating IL-1R1 which re-
sults in an underestimation of IL-1β concentrations by
ELISA [41, 42]. Since cancer cells of epithelial origin can
express IL-1R2 [43, 44], it is possible that in our case
cetuximab/EGFR inhibition may be inducing the release
of IL-1β as well as IL-1α but we are unable to detect
IL-1β due to rapid binding by sIL-1R2. Blocking IL-1R2
expression may reveal detectable levels of IL-1β and is
the subject of further studies in the context of cetuximab
therapy.
IL-1 signaling has been reported in various studies (in-
cluding our own) to be associated with poor prognosis
due to the resulting downstream expression of genes in-
volved in tumor progression including IL-6 and IL-8 [15,
45–48]. In contradiction to IL-1’s tumor-promoting role,
IL-1 signaling has been shown to be involved in tumor
cell killing via an anti-tumor immune response [49–51].
In order to begin to understand how IL-1 signaling may
impact HNSCC tumor response to cetuximab, we
showed that IL-1 blockade using anakinra did not en-
hance or affect tumor response to cetuximab treatment
in both immunodeficient and immunocompetent mouse
models (Fig. 2D-F) suggesting that under the described
experimental conditions, IL-1 signaling may not play a
major role in the anti-tumor efficacy of cetuximab.
However, blocking IL-1 signaling with anakinra does
have some limitations since it has a short half-life (me-
dian 5.7 h) necessitating daily dosing and 100–1000 fold
excess of drug (in relation to IL-1 ligands) is required
for appropriate blockade of IL-1 signaling [37]. Using
the IL-1R1 knockdown SQ20B cells shown in Fig.S 1G-I
in athymic nude mice, we showed that knocking down
the IL-1R1 using both clones (shIL-1R#1 and shIL-1R#2)
did not enhance but partially and significantly reversed
the anti-tumor effect of cetuximab (Additional file 9:
Figure S8). In these particular genetic IL-1R1 knock-
down experiments we used a much higher dose of
cetuximab (6 mg/kg) than the cetuximab dose (2 mg/kg)
utilized for the SQ20B-xenograft mouse models de-
scribed in the main manuscript, which caused a
complete inhibition of tumor growth (Additional file 9:
Figure S8A,B). Despite this high dose, IL-1R1 knock-
down was able to partially reverse the effect of cetuxi-
mab (Additional file 9: Figure S8A,B) which altogether
suggests that IL-1 blockade does not enhance cetuximab
efficacy, but under certain conditions may be detrimen-
tal for optimal cetuximab efficacy.
The important role of IL-1 signaling in anti-tumor im-
mune response [22] provided an opportunity to deter-
mine if an increase in IL-1 signaling would enhance the
efficacy of cetuximab. IL-1 signaling has been proposed
as a key mediator of host defense against malignancies
through its role on NK cell activity (i.e. IFNγ production
and ADCC) [49]. In fact, NK-cell activity can be signifi-
cantly inhibited by anakinra (IL-1RA), or by neutralizing
antibodies for IL-1 ligands [52]. Although we found that
cetuximab in combination with increased IL-1α was
Fig. 7 High serum IL-1α predicts progression free survival (PFS) in HNSCC patients treated with cetuximab-containing therapy. Baseline serum
samples from 11 recurrent and/or metastatic (R/M) HNSCC patients scheduled for cetuximab-based chemotherapy (i.e. carboplatin, cisplatin, 5-FU,
paclitaxel) at the University of Iowa Hospitals and Clinics Holden Comprehensive Cancer Center were collected. Serum IL-1α levels were
measured by ELISA and patients were divided into two groups: detectable (n = 5) and undetectable (n = 6) IL-1α levels. Kaplan Meier survival
curves were plotted for PFS for both groups. HR: hazard ratio; CI: confidence interval
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effective in athymic nude mice (Figs. 3, and 4A) which
are capable of robust NK cell responses, we found no
evidence of NK cell involvement when looking at NK
cell phenotypes in spleens and tumors from immuno-
competent mice (Additional file 5: Figure S4, Additional
file 6: Figure S5). IL-1 is also able to directly enhance
survival of CD4+ T cells and induce secondary CD8+ T
cell responses characterized by enhanced granzyme B
expression and increased IFNγ production [53–55]. In
support of this we observed increased levels of CD8+ T
cells and decreased PD1 + CD4+ and CD25 + CD4+ T
cells in spleens of BALB/c mice administered cetuximab
+IL-1α-NP compared to control (Fig. 5G-I), and T cells
appeared to be required for the anti-tumor mechanism
of IL-1α in particular since rIL-1α (as a single agent)
demonstrated significant anti-tumor activity in BALB/c
mice (Fig. 4B) but not nude mice (Fig. 4A). Furthermore,
depletion of CD4+ and CD8+ T cells significantly re-
versed the effect of cetuximab+IL-1α-NP (Fig. 6) sug-
gesting that IL-1α in combination with cetuximab can
induce a T cell-dependent anti-tumor immune response.
Based on the anti-tumor properties of IL-1 ligands, re-
combinant IL-1 ligands were previously pursued as
anti-cancer agents. Clinical studies conducted the late
1980s and early 1990s have shown that recombinant
IL-1α (marketed as Dainippon and Immunex) can be
safely given to human cancer patients [56]. Unfortu-
nately, dose-related side effects such as hypotension,
fever, vomiting and abdominal pain although manage-
able, resulted in lessened enthusiasm for continued pro-
duction of human rIL-1α for clinical trials. The dramatic
weight loss, lethargy and diarrhea observed in mice dur-
ing rIL-1α treatment supports these prior observations
(Fig. 4C, D). In an attempt to reduce the development of
side effects, we used amphiphilic polyanhydride copoly-
mers based on CPTEG and CPH which have been re-
ported to be excellent delivery systems for various
payloads in oncology and immunology-based research
[57–62]. CPTEG in the copolymer serves to maintain
structural integrity and immunogenicity of the encapsu-
lated immunogen [63]. The amount of CPH in the co-
polymer is associated with longer erosion kinetics [64,
65]. Modification of the monomers or molar ratios in
the copolymer composition of polyanhydrides have been
shown to alter the degradation rate thereby regulating
the release kinetics of the payload [62, 65]. The
IL-1α-NP formulation utilized in this work showed less
than ideal release kinetics in vitro since the majority of
the payload was released in the first 24 h and the re-
mainder slowly released over the next 5 days (Additional
file 4: Figure S3). Nevertheless, in vivo, we show remark-
able tumor regression in 8 of 9 mice with a single ad-
ministration of IL-1α-NPs in combination with
cetuximab (Fig. 5E) with no obvious signs of toxicity
(Fig. 5F) compared to the dramatic weight loss seen with
soluble rIL-1α (Fig. 4C, D). The IL-1α-NP formulation
as a single agent also triggered tumor regression, al-
though in only 6 of the 10 mice in this treatment group
(Fig. 5D), which explains the non-significance of this
treatment group on average compared to the control
(EMP-NP)-treated group (Fig. 5A). These results
demonstrate the clear anti-tumor potential of IL-1α-NP
and the release kinetics appeared to be sufficient to in-
duce a safe and effective anti-tumor immune response
and tumor regression. Further work is ongoing using
additional delivery nanoparticle platforms for IL-1
immunotherapeutic strategies.
The role of IL-1α in anti-tumor response and the contri-
bution to the remarkable tumor regression observed when
in combination with cetuximab led us to inquire if
increased circulating levels of IL-1α could serve as a
predictive biomarker for favorable clinical outcomes in
cetuximab-treated HNSCC patients. To date, there are no
biomarkers used in clinical practice that can predict tumor
response to cetuximab in HNSCC patients despite pre-
dictive biomarkers for response to EGFR inhibitors being
well established in non-small cell lung cancer (NSCLC)
(37) and colorectal cancer (CRC) (38). So far in an on-
going study, we have found clear evidence of significantly
longer PFS in a small cohort (n = 11) of HNSCC patients
(with available clinical outcome data) treated with
cetuximab-based chemotherapy with detectable baseline
IL-1α levels compared to undetectable baseline IL-1α by
ELISA (Fig. 7), suggesting that IL-1α expression may be a
predictive indicator of recurrence or PFS in
cetuximab-based chemotherapy-treated HNSCC patients.
Cetuximab is typically and routinely administered in com-
bination with chemotherapy in R/M HNSCC patients as
standard of care therefore it is likely that our findings will
not be able to be validated in an appropriate homoge-
neous cetuximab-monotherapy-treated HNSCC patient
cohort. The current findings are limited so far by the small
number of patients, however our additional ongoing stud-
ies in cetuximab-based chemo/radiotherapy-treated
HNSCC patient cohorts compared to non-cetuximab-
treated patients from separate independent clinical trials
should assist in validating these findings. Our preliminary
findings of IL-1α as a biomarker for favorable outcome to
cetuximab therapy contradicts conventional knowledge
about IL-1α since IL-1 signaling is believed to be
associated with poor survival outcomes and drug resist-
ance [13, 14]. However we believe that the anti-tumor
immune response associated with IL-1α/IL-1 signaling
can promote an environment which would be benefi-
cial for the success of select agents that trigger
anti-tumor immune responses (including cetuximab,
anti-PD1) and further studies are ongoing to investi-
gate these ideas.
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Conclusions
Overall, immunotherapy is a strategy that is currently
promising for HNSCC patients and based on recent clin-
ical data with T-cell checkpoint inhibitors (anti-PD1) [66,
67], it is clear that promoting an active anti-tumor im-
mune response can be highly therapeutic. This work high-
lights the possible clinical utility of IL-1α-NP as a safe and
novel immunotherapeutic strategy as a single agent and
for use in combination with cetuximab for HNSCC ther-
apy. We believe that safely increasing IL-1 signaling in
combination with cetuximab as a novel immunotherapeu-
tic strategy would be promising in that we would be tar-
geting both the tumor (via EGFR inhibition) resulting in
high response rates, and the host innate and adaptive im-
mune system (via increased T-cell responses) resulting in
more durable tumor responses. This strategy along with
IL-1α as a potential predictive biomarker, would represent
a significant advancement in treatment options for R/M
HNSCC patients where cetuximab-based chemotherapy
remains the standard of care and possibly for other pa-
tients bearing EGFR-expressing tumors.
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